市场调查报告书
商品编码
1361113
无血清培养基市场规模 - 按类型(CHO 细胞培养、蛋白质表现培养基)、应用(生物製药生产、干细胞研究与治疗)、最终用户和全球预测,2023-2032 年Serum-free Media Market Size - By Type (CHO Cell Culture, Protein Expression Media), Application (Biopharmaceutical Production, Stem Cell Research & Therapy), End-user & Global Forecast, 2023-2032 |
由于对先进生物製药产品的需求不断增加,预计 2023 年至 2032 年无血清培养基市场规模的复合年增长率将超过 11%。随着公司不断开发新疗法,他们正在转向无血清培养系统,以提高生产力、一致性和产品品质。
例如,Thermo Fisher Scientific 的 Gibco 提供了一种由必需营养素和激素配製而成的无血清培养基溶液,无需动物血清即可进行细胞培养。在细胞培养中使用无血清培养基带来了一系列优势,包括提高一致性和生产力,以及简化纯化和下游处理。
此外,人们越来越担心血清衍生成分的安全性和污染的可能性,导致人们转向无血清培养基,从而消除了这些风险。此外,对客製化培养解决方案的需求以及针对不同研究和生产要求开发化学成分确定的培养基的需求将进一步提振市场。
整个无血清培养基行业根据类型、应用、最终用户和地区进行分类。
在生物製药产业不断扩张的推动下,蛋白质表现介质领域预计 2023 年至 2032 年复合年增长率将达到 11%。随着研究人员和製造商寻求优化重组蛋白、单株抗体和其他生物製剂生产的产量、品质和一致性,专门为蛋白质表现而设计的无血清培养基的需求量很大。这些培养基类型的配方可支持高细胞密度和提高蛋白质生产率,使其在生物製造领域至关重要。
组织工程和再生医学应用领域预计在2023 年至2032 年期间复合年增长率将达到11.2%。随着再生疗法和组织工程解决方案的发展,针对临床应用细胞培养和扩增而定制的无血清培养基的需求不断增加上升。这些培养基提供支持干细胞和原代细胞生长和分化所需的精确配方,促进器官移植、伤口癒合和个人化医疗等领域的进步。
亚太地区无血清培养基市场规模预计 2023 年至 2032 年复合年增长率为 11.5%。亚太地区生物技术和製药业不断发展,研发投资不断增加。技术进步迅速,并转向生物製药生产。随着人口的增长、医疗保健投资的增加以及主要参与者的出现,亚太地区的无血清培养基市场将进一步发展。
Serum-free media market size is expected to witness over 11% CAGR from 2023 to 2032 due to the increasing demand for advanced biopharmaceutical products. As companies continue to develop novel therapeutics, they are turning to serum-free culture systems to enhance productivity, consistency, and product quality.
For instance, Thermo Fisher Scientific's Gibco, offers a serum-free media solution formulated with essential nutrients and hormones, allowing for cell culture without the need for animal sera. The utilization of serum-free media in cell culture brings about a range of advantages, including enhanced consistency and productivity, as well as streamlined purification and downstream processing.
Additionally, growing concerns about the safety of serum-derived components and the potential for contamination have led to a shift towards serum-free media, which eliminates these risks. Moreover, the need for customized culture solutions and the development of chemically defined media for diverse research and production requirements will further bolster the market.
The overall serum-free media industry is classified based on type, application, end-user, and region.
The protein expression media segment is expected to register 11% CAGR from 2023 to 2032 driven by the expanding biopharmaceutical sector. Serum-free media designed specifically for protein expression are in high demand as researchers and manufacturers seek to optimize yields, quality, and consistency in the production of recombinant proteins, monoclonal antibodies, and other biologics. These media types are formulated to support high cell densities and increased protein productivity, making them essential in the biomanufacturing landscape.
Tissue engineering & regenerative medicine application segment is predicted to record 11.2% CAGR during 2023 to 2032. As regenerative therapies and tissue engineering solutions gain traction, the demand for serum-free media tailored for the culture and expansion of cells for clinical applications is on the rise. These media offer the precise formulation needed to support the growth and differentiation of stem cells and primary cells, facilitating advancements in areas such as organ transplantation, wound healing, and personalized medicine.
Asia Pacific serum-free media market size is expected to observe 11.5% CAGR from 2023 to 2032. Asia Pacific boasts a growing biotechnology and pharmaceutical sector, with increasing investments in R&D. There are rapid technological advancements and a shift toward biopharmaceutical production. The serum-free media market in Asia Pacific will further bolster with a growing population, rising healthcare investments, and the presence of key players.